-57%

est. 2Y upside i

HealthcareSeries D+

Rank

#3753

Sector

Biotechnology / Life Sciences Tools

Est. Liquidity

~3Y

Data Quality

Data: Medium

biomodal operates in a high-growth multiomics market with proprietary 6-base genome technology and recent clinical breakthroughs.

Last updated: March 10, 2026

Bull (15%)+175%

biomodal's proprietary 6-base genome technology achieves rapid market penetration through successful partnerships like Element Biosciences and its Certified Service Provider program, driving significant adoption in cancer and neurodegenerative disease research. Continued breakthroughs in early cancer detection lead to strong revenue acceleration, pushing revenue to ~$63.5M and justifying a valuation of ~$1.27B, representing a substantial return for early equity holders.

Base (35%)+30%

biomodal maintains its niche in the multiomics market, growing steadily but facing persistent competition from incumbents. Revenue reaches ~$40.3M, and the valuation grows modestly to ~$604.5M, reflecting moderate market adoption and some multiple compression, providing a limited but positive return for common shareholders.

Bear (50%)-60%

Intense competition from dominant incumbents like Illumina and Oxford Nanopore Technologies, coupled with prolonged and costly patent infringement lawsuits, stifles biomodal's growth and market expansion. Regulatory hurdles and high capital intensity lead to a down round or acquisition at a significantly lower valuation of ~$186M. Given $164M in liquidation preferences, common shareholders would see their equity value severely eroded, receiving only ~$22M.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Funding Intensity

35%

Investors have contributed $164M, representing 35.3% of the current $465M valuation, meaning they hold significant liquidation preferences ahead of common shareholders. In a $186M exit (bear case), common shareholders would receive only $22M after investors are paid back their $164M.

Dilution Risk

moderate

As a Series D company with high capital intensity, further funding rounds are possible, which could lead to additional dilution for existing equity holders.

Secondary Liquidity

limited

Secondary liquidity for private companies at this stage is typically limited, often relying on specific tender offers or infrequent opportunities.

View all 3 open roles at biomodal →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on biomodal's data — designed to show you've done your homework.

  • 1

    “How is biomodal planning to navigate and defend its market position against dominant incumbents like Illumina and Oxford Nanopore Technologies, especially given their vast resources and established customer bases?”

  • 2

    “With current revenue around $22M and a significant TAM, what are the specific strategies and milestones for accelerating revenue growth and expanding market penetration for your duet multiomics solutions over the next 2-3 years?”

  • 3

    “Given the Series D funding in late 2021 and the current valuation, what is the company's anticipated timeline and strategy for a liquidity event (e.g., IPO or acquisition) for employees, and how is the preference stack being managed to ensure common shareholder value?”

Community

Valuation Sentiment

Our model estimates -57% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.